In a patient who tested positive for Mycoplasma hominis and Ureaplasma parvum and has no known macrolide allergy, can azithromycin be used to treat both infections?

Azithromycin for Mycoplasma hominis and Ureaplasma parvum Co-infection

Yes, azithromycin can be used to treat both Mycoplasma hominis and Ureaplasma parvum infections, though its effectiveness varies between the two organisms and resistance patterns must be considered.

Treatment Recommendation

Azithromycin 1g orally as a single dose is an appropriate first-line treatment for this co-infection, particularly given its FDA-approved indication for urethritis and cervicitis due to various pathogens 1 and guideline support for nongonococcal urethritis 2. However, you should be aware of important susceptibility differences between these organisms.

Organism-Specific Considerations

Ureaplasma parvum

• Good susceptibility: Azithromycin demonstrates effective activity against U. parvum with MIC90 values of 1 mcg/ml 3
• Initial MIC of 4 mcg/ml for Ureaplasma species generally 4
• Clinical success documented in multiple case reports 5, 6, 7

Mycoplasma hominis

• Variable susceptibility: M. hominis shows "some resistance" to azithromycin 4
• M. hominis has intrinsic resistance to macrolides due to lack of 23S rRNA binding sites 8
• Despite this, clinical success has been reported when azithromycin is combined with other agents 6

Critical Caveats

Resistance is emerging: Recent surveillance data shows:

• Macrolide resistance in genital mycoplasmas is increasing globally 8
• Fluoroquinolone resistance in Ureaplasma spp. reaches 79.3% in some regions 9
• Tetracycline resistance occurs in 12.9% of Ureaplasma isolates 10

For M. hominis specifically: Given its intrinsic macrolide resistance, if symptoms persist after azithromycin monotherapy, you should add or switch to:

• Doxycycline 100mg orally twice daily for 7 days (alternative per guidelines 2)
• Tetracyclines show 71.8% susceptibility for M. hominis 9
• Clindamycin is another option for M. hominis with minimal resistance (7.7%) 10

Practical Algorithm

1. Initial treatment: Azithromycin 1g single dose
2. Follow-up at 1 month: Assess symptom resolution 7
3. If symptoms persist:
   • Obtain susceptibility testing if available
   • Switch to doxycycline 100mg twice daily for 7 days 2, 7
   • Consider combination therapy (azithromycin + doxycycline or minocycline) for severe or recurrent cases 6

Supporting Evidence

The 2006 CDC STD Treatment Guidelines explicitly recommend azithromycin 1g as first-line for nongonococcal urethritis 2, and the FDA label confirms its indication for urethritis due to multiple pathogens 1. Clinical case reports demonstrate successful treatment of U. parvum and M. hominis co-infections with azithromycin 5, and a study of 81 women with Ureaplasma showed 95.1% cure rates with azithromycin 1g, with the remaining 4.9% responding to doxycycline 7.

The key limitation: M. hominis has intrinsic macrolide resistance, so while azithromycin may work for the U. parvum component, you may need to add tetracycline coverage if M. hominis is the predominant pathogen or if clinical response is inadequate.